Study guide

18.3 Cytokine Release Syndrome

Certified Pediatric Hematology Oncology Nurse CPHON®

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy

2 Care Continuum

2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship

3 Leukemias and Lymphomas

3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas

4 CNS, Neuroblastoma, and Renal Tumors

4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors

5 Sarcomas and Other Solid Tumors

5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors

6 Hematologic Disorders

6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure

7 Pathophysiology, Genetics, and Diagnostics

7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis

8 Clinical Trials and Professional Performance

8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education

9 Chemotherapy and Biotherapy

9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy

10 Immunotherapy, Cellular Therapy, and Radiation

10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam

11 HSCT, Surgery, Transfusion, and Coagulation Therapy

11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy

12 Neurologic, Respiratory, and Cardiovascular Effects

12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects

13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects

13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects

14 Endocrine, Hematologic, Immunologic, and Sensory Effects

14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects

15 Pain, Sleep, Fatigue, and Mental Health

15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects

16 Supportive Care

16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care

17 Infectious and Gastrointestinal Emergencies

17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction

18 Metabolic Emergencies

18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome

19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome

19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)

20 Sickle Cell and Hemostasis Emergencies

20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed

21 Cardiopulmonary Emergencies

21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias

22 Neurologic and Infusion Emergencies

22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation

23 Family, Caregivers, and Social Integration

23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment

24 Development, Grief, Culture, and Community Resources

24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources

18.3 Cytokine Release Syndrome

Key Takeaways Explain This Topic AI

CRS after CAR-T and bispecifics such as blinatumomab starts with fever, then hypoxia, hypotension, and capillary leak, hours to days after infusion.

ASTCT-style grading is a known concept: fever opens the grade, and oxygen or vasopressor need raises it; do not memorize every device cutoff as if ONCC published the table.

Tocilizumab is the targeted IL-6-receptor treatment for CRS that meets protocol criteria; corticosteroids treat refractory CRS and ICANS overlap.

Give fluids carefully because capillary leak floods the lungs; escalate to ICU for shock or high oxygen need rather than stacking boluses.

Fever after immune-effector therapy is sepsis until proven otherwise: culture and give antibiotics while treating CRS—do not pick only one.

Last updated: August 2026

CPHON TCO V.C.4 is cytokine release syndrome (CRS) as an emergency , not as a manufacturing lecture. The full chimeric antigen receptor T-cell (CAR-T) sequence—leukapheresis, lymphodepleting fludarabine plus cyclophosphamide , infusion, expansion, and B-cell aplasia with intravenous immunoglobulin—lives in the cellular-therapy chapter. This section is what you do when fever, leak, hypoxia, and hypotension start hours to days after the cells or the bispecific antibody are in the child.

Who gets CRS and when

CRS follows immune-effector cell therapy : CD19 CAR-T for relapsed or refractory B-ALL (and some lymphomas) and bispecific T-cell engagers such as blinatumomab (a continuous CD19/CD3 infusion). Other T-cell–engaging antibodies can do the same. It is interleukin-6 (IL-6) –driven macrophage and T-cell activation, not a simple drug fever and not graft-versus-host disease from a transplant graft. CAR-T is not hematopoietic stem cell transplantation.

Timing is hours to days after infusion , product-dependent. Blinatumomab CRS often declares on the first cycle , sometimes within hours of the bag starting or the rate stepping up. CAR-T CRS commonly appears during in vivo expansion in the first many days after infusion, not during the manufacturing week when the child is still waiting for the bag. A 9-year-old who looks well the evening of CAR-T infusion and spikes 39.2°C on day 4 is in the CRS window until proven otherwise. A 7-year-old whose parent disconnected a blinatumomab pump and who then becomes febrile and hypotensive after restart is also in the CRS window—and the line interruption is a separate medication-safety event.

Do not teach that CRS “only happens in the ICU after transplant.” Do not teach that isolated fever two days after cells “cannot be CRS because it is too late” or “too early.” Hours to days is the exam range.

Fever first, then leak

Fever is the first and grade-defining clinical move in commonly used systems. Then comes capillary leak : third-spacing, edema, weight gain, pulmonary edema, hypoxia , and hypotension . Coagulopathy, transaminitis, and tachycardia travel with higher-grade disease. A child can climb from “just febrile” to vasopressor shock in hours. That is why cellular-therapy fever is a stay-and-notify finding, not a playroom suggestion.

American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading is the language most pediatric cellular-therapy programs use. Teach the concept , not a claim that ONCC printed the table:

Grade opens with fever .

The grade rises when hypotension needs more than fluids (vasopressors) or when hypoxia needs increasing oxygen support.

Higher grades are ICU physiology : pressors, high-flow oxygen, positive-pressure ventilation.

You will not be scored on reciting every oxygen-device cutoff as if it were an ONCC fact. You will be scored on recognizing that fever plus leak is CRS, that oxygen and blood pressure define severity, and that the floor is not the place to “watch” refractory shock.

A 9-year-old on nasal cannula with a falling blood pressure is already a different grade from the same child who was only febrile an hour ago. Call early. Serial vital signs, work of breathing, and weights catch leak before the chest radiograph does.

Tocilizumab, steroids, fluids, ICU

Tocilizumab , an IL-6 receptor antagonist , is the targeted drug for CRS that meets protocol treatment criteria (typically hypotension, hypoxia, or a rapid grade rise—not every isolated low-grade fever). Give it as ordered. Do not wait for a code. Repeat doses follow the product protocol.

Corticosteroids (often dexamethasone) treat refractory CRS and are first-line for significant immune effector cell–associated neurotoxicity syndrome (ICANS) overlap: aphasia, seizure, ICE-style encephalopathy, cerebral edema. For many CRS protocols, steroids come after tocilizumab because they can dampen CAR-T activity. Isolated ICANS without CRS is a steroid-and-neuro problem; tocilizumab is not the automatic first drug for a child who is only aphasic and not leaking. ICE-style checks still run on a clock during the CRS window. A 12-year-old who cannot write her name the morning after fever is ICANS until proven otherwise, even if blood pressure has recovered.

Fluids are given carefully. Capillary leak means the bolus you would give a septic toddler can flood the lungs. Use protocol-sized boluses, reassess, and move to vasopressors and ICU rather than stacking milliliters. Weigh every shift. Crackles plus a 1-kg gain in a 20-kg child is leak.

Rule out sepsis and treat both until proven. Febrile neutropenia plus CRS is not a multiple-choice fork where you pick only one. Culture, give broad-spectrum antibiotics per fever-and-neutropenia protocol, and treat CRS. Withholding antibiotics “to protect the cells” is how children die of bacterial sepsis that looked like grade 1 CRS. Conversely, antibiotics alone without notifying the cellular-therapy team miss the IL-6 emergency.

Stop or hold blinatumomab per protocol for CRS; never bolus a continuous bag to “catch up” after a pause. CAR-T cells are already in; you cannot take them back, so management is tocilizumab, support, steroids as indicated, and organ support. Premedication and line-security rules for blinatumomab belong with immunotherapy administration; the emergency product here is fever-then-leak after the bag is already running.

A pediatric picture that holds

A 9-year-old day-4 post CD19 CAR-T: fever 39.4°C, then nasal-cannula oxygen, then a falling blood pressure with puffy eyelids. Culture and antibiotics. Notify. Tocilizumab as ordered. Careful fluids. Telemetry and ICE-style neuro checks because ICANS may follow. ICU when oxygen or blood pressure is no longer a floor problem. A 7-year-old on blinatumomab with the same physiology: hold the infusion, same dual infection-plus-CRS path, same tocilizumab conversation, same leak-aware fluids. A toddler too young for a classic ICE score still gets a neurologic check: tracking, speech, seizure watch, and a low threshold to call.

Finding Meaning Action

Fever hours to days after CAR-T or blinatumomab First CRS sign; also possible sepsis Culture, antibiotics, notify

  • Hypoxia or hypotension ASTCT-style grade is rising Oxygen, careful fluids, tocilizumab
  • Capillary leak / edema Third-spacing Limit stacked boluses; ICU if lungs wet
  • Refractory shock or high O2 High-grade CRS ICU, pressors, steroids as ordered
  • Aphasia, seizure, ICE-style fail ICANS overlap Steroids, seizure precautions, airway

That is the emergency chapter: fever first, dual-treat infection, grade by oxygen and blood pressure, tocilizumab for CRS, steroids for refractory disease and ICANS, fluids with leak in mind, hours-to-days timing, and no CAR-T factory lecture on this page.

Loading diagram... CRS emergency path after CAR-T or blinatumomab